This clinical-stage biotech focused on precision medicines for renal and metabolic diseases just reported a notable insider ...
南旧金山 - Maze Therapeutics Inc. (NASDAQ:MAZE)周三公布第四季度每股亏损$0.65,此前其主要候选药物的2期临床试验结果呈阳性。 该公司股价在盘前交易中飙升22.18%。
This pharmaceutical company's executive sold all his direct shares less than a month before a highly anticipated earnings ...
Maze Therapeutics (NASDAQ:MAZE) outlined positive Phase II results from its open-label HORIZON study evaluating MZE829 in ...
Maze Therapeutics has revealed topline phase 2 data for its lead kidney disease candidate that has analysts heralding its ...
Besting Vertex Pharmaceuticals’ kidney disease asset wasn’t enough to impress Wall Street, which appears to be “getting hung ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果